Guangzhou Kingmed Diagnostics Group Co Ltd
SSE:603882

Watchlist Manager
Guangzhou Kingmed Diagnostics Group Co Ltd Logo
Guangzhou Kingmed Diagnostics Group Co Ltd
SSE:603882
Watchlist
Price: 28.72 CNY 0.67% Market Closed
Market Cap: 13.3B CNY

Guangzhou Kingmed Diagnostics Group Co Ltd
Net Issuance of Debt

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Guangzhou Kingmed Diagnostics Group Co Ltd
Net Issuance of Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Debt CAGR 3Y CAGR 5Y CAGR 10Y
Guangzhou Kingmed Diagnostics Group Co Ltd
SSE:603882
Net Issuance of Debt
ÂĄ133.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Jinxin Fertility Group Ltd
HKEX:1951
Net Issuance of Debt
-ÂĄ110.4m
CAGR 3-Years
-49%
CAGR 5-Years
-33%
CAGR 10-Years
N/A
Topchoice Medical Co Inc
SSE:600763
Net Issuance of Debt
-ÂĄ45m
CAGR 3-Years
24%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Nanjing Xinjiekou Department Store Co Ltd
SSE:600682
Net Issuance of Debt
-ÂĄ41.3m
CAGR 3-Years
43%
CAGR 5-Years
N/A
CAGR 10-Years
6%
Dian Diagnostics Group Co Ltd
SZSE:300244
Net Issuance of Debt
-ÂĄ944.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Meinian Onehealth Healthcare Holdings Co Ltd
SZSE:002044
Net Issuance of Debt
ÂĄ395.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
3%
No Stocks Found

Guangzhou Kingmed Diagnostics Group Co Ltd
Glance View

Market Cap
13.3B CNY
Industry
Health Care

Guangzhou Kingmed Diagnostics Group Co Ltd has crafted its journey in the healthcare industry with precision and analytical prowess. Emerging in the early 2000s, Kingmed Diagnostics tapped into a burgeoning market niche—offering diagnostic testing services to hospitals, clinics, and other medical institutions. With a blend of advanced technology and extensive scientific expertise, the company provides a range of services, from routine clinical testing to esoteric evaluations that require more sophisticated techniques. Kingmed’s laboratories, strategically established across China, facilitate a seamless operation that processes millions of tests annually, ensuring timely and accurate results. This operational efficiency not only supports healthcare providers in delivering informed patient care but also positions Kingmed at the forefront of diagnostic innovation. Revenue streams flow through service contracts with healthcare facilities and direct partnerships where they provide specialized testing offerings that institutions may not have the infrastructure to perform in-house. By leveraging economies of scale, Kingmed achieves cost efficiencies, which in turn afford competitive pricing structures, further securing its market position. Complementing its robust diagnostic services, the company also invests in research and development initiatives, continuously enhancing its test portfolio. This commitment to innovation ensures that they stay relevant in the ever-evolving healthcare landscape, capturing new opportunities and expanding their market reach. Through this strategic framework, Guangzhou Kingmed Diagnostics not only sustains its financial growth but also fortifies its leadership in the diagnostic services sector.

Intrinsic Value
29.46 CNY
Undervaluation 3%
Intrinsic Value
Price

See Also

What is Guangzhou Kingmed Diagnostics Group Co Ltd's Net Issuance of Debt?
Net Issuance of Debt
133.4m CNY

Based on the financial report for Sep 30, 2025, Guangzhou Kingmed Diagnostics Group Co Ltd's Net Issuance of Debt amounts to 133.4m CNY.

What is Guangzhou Kingmed Diagnostics Group Co Ltd's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 1Y
-43%

Over the last year, the Net Issuance of Debt growth was -43%.

Back to Top